Novavax | NVAX - الأصول





الأصول تغيير تاريخ
Adma Biologics USD 665.18M 40.94M 2026-03
Agenus USD 186.46M 40.34M 2026-03
AstraZeneca USD 114.02B 59M 2026-03
BioCryst Pharmaceuticals USD 465.05M 49.11M 2026-03
Cassava Sciences USD 108.37M 9.99M 2026-03
Geron USD 534.12M 36.42M 2026-03
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
MannKind USD 744.4M 47.78M 2026-03
Merck USD 128.68B 8.18B 2026-03
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Moderna USD 11.49B 850M 2026-03
Novartis USD 110.95B 3.66B 2025-12
Novavax USD 1.04B 133.35M 2026-03
Pfizer USD 207.62B 542M 2026-03
Sanofi EUR 128.02B 1.22B 2026-03
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
TG Therapeutics USD 1.53B 465.58M 2026-03